Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 6Recruiting 3Terminated 2Withdrawn 1Unknown 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 26Melanoma 25Stomach Neoplasms 9Neoplasms 8Carcinoma, Renal Cell 7Carcinoma, Hepatocellular 6Squamous Cell Carcinoma of Head and Neck 5Neoplasm Metastasis 5Hodgkin Disease 5Breast Neoplasms 5Triple Negative Breast Neoplasms 4Urinary Bladder Neoplasms 3Prostatic Neoplasms 3Pancreatic Neoplasms 3Lung Neoplasms 3Head and Neck Neoplasms 3Esophageal Squamous Cell Carcinoma 3Uveal Melanoma 2Small Cell Lung Carcinoma 2Sarcoma 2Recurrence 2Mesothelioma, Malignant 2Lymphoma, B-Cell 2Leukemia, Myeloid, Acute 2Gastrointestinal Neoplasms 2Esophageal Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Merkel Cell 2Carcinoma 2Brain Neoplasms 2

Interventions

Gemcitabine 9Oxaliplatin 6Cisplatin 6Capecitabine 6durvalumab 4apatinib 4S 1 (combination) 4Irinotecan 4Immune Checkpoint Inhibitors 4surufatinib 3Injections 3Drug Therapy 3pembrolizumab 2lenvatinib 2camrelizumab 2Taxes 2Leucovorin 2Fluorouracil 2Docetaxel 2130-nm albumin-bound paclitaxel 2tremelimumab 1toripalimab 1taxane 1spartalizumab 1sintilimab 1regorafenib 1manganese chloride 1irinotecan sucrosofate 1gimeracil 1gemcitabine-oxaliplatin regimen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Biliary Tract Neoplasms × Nivolumab × Clear all
NCT03311789 2017-10-17

Study of PD-1 Inhibitor in Combination With Gemcitabine/Cisplatin for Advancer BTCs

Chinese PLA General Hospital

Phase 1/2 Unknown
30 enrolled
Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡